Slide 1: Patrys presents to investors in Australia and Asia (ASX & Media Release)
ASX & Media Release PATRYS PRESENTS TO INVESTORS IN AUSTRALIA AND ASIA For personal use only Melbourne, Australia; 9 March 2011: Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is today presenting to professional and institutional investo
Slide 2: Natural Human Antibodies: A New Paradigm for the Treatment of Cancer
For personal use only Natural Human Antibodies: A New Paradigm for the Treatment of Cancer Investor Presentation 9 March 2011 Dan Devine Chief Executive Officer
Slide 3: Company Overview
Company Overview For personal use only Objective Develop completely new treatments for cancer and maintain first mover advantage Business Advance select programs to human proof of concept – key inflection point for new molecules Strategy Leverage deep pipeline via internal development and part
Slide 4: Need for New Cancer Treatments
Need for New Cancer Treatments For personal use only Current Approach Patient Need Results (Proteomics – Genomics) Develop drugs against genes or proteins more prevalent in Little recent cancer vs. healthy tissues improvement in survival While lower in expression, these drug targets are also
Slide 5: Natural Human Antibodies: A New Paradigm
Natural Human Antibodies: A New Paradigm Research groups have shown that For personal use only human body makes antibodies that: Bind to “targets” on cancer cells Natural Human Antibody Kill cancer cells Scientific Publications Don’t attack healthy human tissues Discussion Number Prevent c
Slide 6: Tech Assets/Competitive Position
Tech Assets/Competitive Position For personal use only Disease Target Discovery 40,000 Clinical antibodies 250 antibodies Further Lead product candidates PAT-SM6 captured & passed characterise nomination; moved to Melanoma screened for primary 10 antibodies further large scale anti-cancer manuf. Tri
Slide 7: PAT-SC1 Lead Product
PAT-SC1 Lead Product Natural human antibody isolated from For personal use only Overview gastric cancer patient PAT-SC1 binds to CD55 protein expressed PAT-SC1 on cancer cells but not healthy cells PAT-SC1 Target: Expressed in >70% of primary gastric Binding CD55 tumours and >95% of metastases
Slide 8: PAT-SC1 Clinical Trial Development
PAT-SC1 Clinical Trial Development 35 gastric cancer patients with tumours For personal use only Patients Treated expressing CD55 Treatment with 20 mg of PAT-SC1; 48 hours later tumour removal Design Safety evaluated Anti-tumour activity measured Patients tracked for survival Significant
Slide 9: PAT-LM1 Lead Product
PAT-LM1 Lead Product Potent killing activity to multiple cancers For personal use only Lung Cancer Animal Model Broad including colon, pancreatic, lung, ovary, Applications prostate Successful completion of safety study Safety sufficient for Phase I single dose human study Successful establish
Slide 10: PAT-SM6 Lead Product
PAT-SM6 Lead Product For personal use only Natural human antibody isolated from cancer patient: Overview Potent killing activity across a range GRP78 of cancers Binds to a protein called GRP78 that is expressed in 98% of cancer tissues Target: screened, but not healthy cells GRP78 Substantia
Slide 11: PAT-SM6 Melanoma Trial and Beyond
PAT-SM6 Melanoma Trial and Beyond For personal use only PAT-SM6 Clinical Development Trial Current Trial 2nd Trial Indication Melanoma Melanoma No. Patients 9 18 Maximum Dose 42 mg 630 mg Primary Endpoints Safety Safety Secondary Endpoints Anti-tumour effect Anti-tumour effect Cancer Centres Royal A
Slide 12: Pipeline Drives Strategy
Pipeline Drives Strategy For personal use only Deep pipeline from same platform but with unique attributes Supports strategy of combining internal development with partnering Flexibility in terms of stage and structure of collaborations Platform generates two new pipeline antibodies per year
Slide 13: CSL Collaboration – Early Partnering
CSL Collaboration – Early Partnering For personal use only Covers 4 early stage assets Driven by CSL interest in disease targets and antibodies Work at CSL Multi-stage/milestone structure First milestone achieved and related payment made to Patrys 1HCY2011 expect next results 12
Slide 14: Other Natural Human Antibody Deals
. . . Other Natural Human Antibody Deals For personal use only Pfizer – Theraclone transaction closed January 2011 Multi-year research and development collaboration Theraclone’s I-START technology to screen natural human antibodies against four undisclosed targets in the areas of infectious di
Slide 15: Recent Advances in Value Proposition
Recent Advances in Value Proposition For personal use only Antibody Therapeutic Sales Overall Antibody M&A - Industry Deal Activity in and Acceptance by Medical Licensing Transaction Natural Human Antibody and Payor Groups Values Space Market Clinical Development of Research Community Positive Resea
Slide 16: Looking Ahead to CY2011
. . . Looking Ahead to CY2011 For personal use only PAT-SM6 human clinical trial data (1H) Initiate larger PAT-SM6 trial (late 1H/early 2H) PAT-SC1 & PAT-LM1 ready for clinical production (2H) Results from collaboration with CSL Limited (1H) Potential new strategic transactions (1H/2H) 15
Slide 17: For Further Information
For Further Information For personal use only Contact Details Dan Devine, Chief Executive Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com 16
Slide 18: Appendix
For personal use only Appendix 17
Slide 19: Milestones Achieved
Milestones Achieved For personal use only Acquisition of clinical product PAT-SC1 Oct 2009 CSL collaboration signed Jan 2010 First CSL milestone reached earning payment May 2010 Strengthening of key 3 new lead products from internal library June 2010 value drivers Acquire late preclinical produ
Slide 20: Financial Overview
Financial Overview For personal use only Listing ASX (Jul 2007): PAB Share Registry Shares 243,069,742 on Issue Market Founders/ $23 million Cap Management Retail 39% 46% Cash $7.7 million (Dec 2010) Institutional Average 2008: 50,000 15% Daily 2009: 140,000 Volume 2010: 310,000 19
Slide 21: PAT-SM6 Lead Product: What Are Others Saying Re: GRP78 Target?
PAT-SM6 Lead Product What Are Others Saying Re: GRP78 Target? For personal use only Growing focus on Biochem. J. 2011: . . . the finding that GRP78 is present on the surface of cancer but not normal cells in vivo represents a promise of GRP78 for paradigm shift and provides an opportunity for canc
Slide 22: PAT-SC1 Lead Product: What Are Others Saying Re: CD55 Target?
PAT-SC1 Lead Product What Are Others Saying Re: CD55 Target? For personal use only Over 255 reports on Pubmed.gov cite CD55 and Cancer Res. 2011.. Cancer cells expressing CD55 result in cancer resistance to multi-billion dollar antibody rituximab. Rising interest in role of CD55 Curr. Cancer Dru
Slide 23: PAT-LM1 Lead Product: What Are Others Saying Re: NONO Target?
PAT-LM1 Lead Product What Are Others Saying Re: NONO Target? For personal use only Biochem. Mol. Biol. 2005... NONO upregulated in resistant prostate cancer cells as they are deprived of serum or growth Approximately 40 papers cite factors. Upregulation of NONO observed to offset apoptosis; role o
Slide 24: Patent Portfolio
Patent Portfolio For personal use only Priority Family Dates Broad protection of molecules, disease PAT-SC1 1998 targets, mechanism of action, uses and PAT-PA1 2001 manufacturing PAT-CM1 2002 PAT-LM1 2003, 2009, 2010 Unique and differentiating position in PAT-CM2 2002 increasingly competitive an
Slide 25: Patrys – Reaching Commercial Yields
Patrys – Reaching Commercial Yields For personal use only Patrys has now moved manufacturing of four products into PER.C6 GMP production cell line Work done by third party collaborator (Percivia, a joint venture between large biotech companies Crucell and DSM) Products from PER.C6 cell line ha
Slide 26: PAT-SM6 Production
PAT-SM6 Production For personal use only Laureate Biopharmaceuticals (www.lbios.com) PAT-SM6 is manufactured at Laureate Biopharmaceutical Services Continuous operation in its Princeton, December Production Run: New Jersey facility since 1981 25X times larger reactor than production Focused